The National Cancer Institute’s Precision Medicine Initiatives NCI-MATCH (Molecular Analysis for Therapy Choice) • Launched in 2015, NCI-MATCH is a precision medicine trial to evaluate whether the choice of treatment can be based on genetic changes present in tumors. • The NCI-MATCH trial led FDA to approve the combination of dabrafenib and trametinib to treat any cancer carrying a genetic alteration in the BRAF gene (1,109). Childhood Cancer Data Initiative (CCDI) Launched in 2019, CCDI aims to: • Gather data from every child, adolescent, and young adult (AYA) diagnosed with a childhood cancer, regardless of where they receive their care; • Create a national strategy of appropriate clinical and molecular characterization to speed diagnosis and inform treatment for all types of childhood cancers; • Develop a platform and tools to bring together clinical care and research data that will improve prevention, treatment, quality of life, and survivorship for childhood cancers. Molecular Characterization Initiative (MCI) • Launched in 2022 as a part of the CCDI, MCI is a national collaboration between the childhood cancer community, advocates, pediatric oncologists, researchers, data scientists, children and AYAs with cancer, and families. • MCI provides state-of-the-art molecular characterization at the time of diagnosis that helps participants and doctors select the best and most appropriate treatment. ComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice) Launched in 2023, ComboMATCH is a group of precision medicine cancer clinical trials, with the goal to determine whether treating cancer with combinations of drugs targeting specific genetic changes improves outcomes (110). SIDEBAR 9 Understanding the Path to Cancer Development AACR Cancer Progress Report 2023 37
RkJQdWJsaXNoZXIy NTkzMzk=